Does TRT really delay biochemical recurrence after radical prostatectomy (in selected patients)?

Some data presented a few weeks ago at the annual meeting of the European Association for Urology appear to have surprised not only the study’s authors, but pretty much everyone else as well. … READ MORE …

Agent Orange and prostate cancer-specific survival on ADT

A newly published article in this month’s Journal of Urology has suggested that being exposed to Agent Orange and getting prostate cancer comes with better overall survival data than if one gets prostate cancer some other way. … READ MORE …

No mortality benefit from dietary supplements … says Harvard and Tufts

The issue of whether routine use of dietary supplements has any meaningful therapeutic benefit has long been a controversial issue (and we don’t expect that to change as a result of what appears below, but …) … READ MORE …

FDA approves new type of PSA testing methodology

According to a report on the US Food and Drug Administration (FDA) web site, the FDA has just approved the “finger-prick” Sangia Total PSA blood test developed by OPKO Diagnostics. … READ MORE …

Next-generation imaging in the management of advanced prostate cancer

A new article in the most recent issue of the Journal of Urology provides recommendations for clinicians as to the appropriate, current use of “next-generation” imaging in the treatment of advanced prostate cancer. … READ MORE …

Curing mice with prostate cancer!

So some readers will already have seen the article in today’s New York Times entitled “Cancer’s trick for dodging the immune system“. … READ MORE …

Restore – a clinical trial for MsM with prostate cancer

The Restore study is a new, NIH/NCI-funded, clinical trial designed to explore what will help gay, bisexual, and other men who have sex with men (collectively, MsM) to recover urinary, sexual, and erectile function after treatment for prostate cancer. … READ MORE …